The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 26, 2025
Filed:
Jul. 29, 2020
Applicant:
Vanderbilt University, Nashville, TN (US);
Inventors:
William P. Tansey, Brentwood, TN (US);
Stephen W. Fesik, Nashville, TN (US);
Shaun R. Stauffer, Brentwood, TN (US);
Alex G. Waterson, Nashville, TN (US);
Changho Han, Nashville, TN (US);
Joseph R. Alvarado, Cleveland Heights, OH (US);
Jonathan D. Macdonald, Nashville, TN (US);
Selena Chacon Simon, Nashville, TN (US);
Sameer S. Nikhar, Nashville, TN (US);
Alexey Kuznetsov, Nashville, TN (US);
Assignee:
Vanderbilt University, Nashville, TN (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 311/21 (2006.01); C07C 311/29 (2006.01); C07C 311/39 (2006.01); C07C 311/43 (2006.01); C07C 317/34 (2006.01); C07C 317/38 (2006.01); C07C 317/48 (2006.01); C07C 323/49 (2006.01); C07C 381/00 (2006.01); C07D 205/04 (2006.01); C07D 207/08 (2006.01); C07D 207/12 (2006.01); C07D 207/27 (2006.01); C07D 211/48 (2006.01); C07D 213/40 (2006.01); C07D 213/56 (2006.01); C07D 213/64 (2006.01); C07D 215/36 (2006.01); C07D 233/36 (2006.01); C07D 239/26 (2006.01); C07D 241/04 (2006.01); C07D 249/14 (2006.01); C07D 265/30 (2006.01); C07D 305/08 (2006.01); C07D 307/14 (2006.01); C07D 307/18 (2006.01); C07D 307/22 (2006.01); C07D 307/52 (2006.01); C07D 307/79 (2006.01); C07D 309/04 (2006.01); C07D 309/10 (2006.01); C07D 309/14 (2006.01); C07D 309/22 (2006.01); C07D 333/20 (2006.01); C07D 333/24 (2006.01);
U.S. Cl.
CPC ...
C07C 311/21 (2013.01); C07C 311/29 (2013.01); C07C 311/39 (2013.01); C07C 311/43 (2013.01); C07C 317/34 (2013.01); C07C 317/38 (2013.01); C07C 317/48 (2013.01); C07C 323/49 (2013.01); C07C 381/00 (2013.01); C07D 205/04 (2013.01); C07D 207/08 (2013.01); C07D 207/12 (2013.01); C07D 207/27 (2013.01); C07D 211/48 (2013.01); C07D 213/40 (2013.01); C07D 213/56 (2013.01); C07D 213/64 (2013.01); C07D 215/36 (2013.01); C07D 233/36 (2013.01); C07D 239/26 (2013.01); C07D 241/04 (2013.01); C07D 249/14 (2013.01); C07D 265/30 (2013.01); C07D 305/08 (2013.01); C07D 307/14 (2013.01); C07D 307/18 (2013.01); C07D 307/22 (2013.01); C07D 307/52 (2013.01); C07D 307/79 (2013.01); C07D 309/04 (2013.01); C07D 309/10 (2013.01); C07D 309/14 (2013.01); C07D 309/22 (2013.01); C07D 333/20 (2013.01); C07D 333/24 (2013.01);
Abstract
Substituted N-phenyl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.